The "Glucose Goddess" built a brand around her blood sugar balancing hacks. She said a few swaps to her diet boosted her mood ...

With patent protection on Danish multinational Novo Nordisk’s blockbuster GLP-1 diabetes drug semaglutide (Ozempic) set to ...

Casey Means has criticized the birth control pill, fearmongered about vaccines, and touted supplements with weak evidence behind them.

Novo Nordisk India MD Vikrant Shrotriya says Semaglutide represents one of the most significant scientific advancements in ...

If you've been managing diabetes based solely on your HbA1c report every three months, you might be flying blind between appointments, and making decisions based on incomplete information.

The collaboration brings together Novo Nordisk’s global GLP-1 leadership and Abbott’s strong India footprint, helping more ...

Abbott and Novo Nordisk partner to launch Extensior (Semaglutide) in India for type 2 diabetes management. Improves metabolic, renal & cardio health.

Abbott partners with Novo Nordisk to launch Extensior, a second Ozempic brand for type 2 diabetes management in India.

Abbott partners with Novo Nordisk India to launch Extensior, a semaglutide-based GLP-1 therapy, expanding access to advanced type 2 diabetes treatment with benefits across blood sugar, weight and ...

Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses risk dilution, mounting debt, or even ...

The companies announced that Abbott will commercialise the drug in India while Novo Nordisk supplies the molecule, which is globally known as Ozempic.